IBDEI0JP ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8668,0)
 ;;=J1642^^68^586^23^^^^1
 ;;^UTILITY(U,$J,358.3,8668,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8668,1,2,0)
 ;;=2^J1642
 ;;^UTILITY(U,$J,358.3,8668,1,3,0)
 ;;=3^HEPARIN SODIUM INJ PER 10 U (FLUSH)
 ;;^UTILITY(U,$J,358.3,8669,0)
 ;;=J1644^^68^586^24^^^^1
 ;;^UTILITY(U,$J,358.3,8669,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8669,1,2,0)
 ;;=2^J1644
 ;;^UTILITY(U,$J,358.3,8669,1,3,0)
 ;;=3^HEPARIN SODIUM INJ PER 1000 U
 ;;^UTILITY(U,$J,358.3,8670,0)
 ;;=J2060^^68^586^30^^^^1
 ;;^UTILITY(U,$J,358.3,8670,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8670,1,2,0)
 ;;=2^J2060
 ;;^UTILITY(U,$J,358.3,8670,1,3,0)
 ;;=3^LORAZEPAM INJ PER 2 MG
 ;;^UTILITY(U,$J,358.3,8671,0)
 ;;=J2405^^68^586^34^^^^1
 ;;^UTILITY(U,$J,358.3,8671,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8671,1,2,0)
 ;;=2^J2405
 ;;^UTILITY(U,$J,358.3,8671,1,3,0)
 ;;=3^ONDANSETRON HCL INJ PER 1 MG
 ;;^UTILITY(U,$J,358.3,8672,0)
 ;;=J2997^^68^586^3^^^^1
 ;;^UTILITY(U,$J,358.3,8672,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8672,1,2,0)
 ;;=2^J2997
 ;;^UTILITY(U,$J,358.3,8672,1,3,0)
 ;;=3^ALTEPLASE RECOMBINANT PER 1 MG
 ;;^UTILITY(U,$J,358.3,8673,0)
 ;;=J3260^^68^586^43^^^^1
 ;;^UTILITY(U,$J,358.3,8673,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8673,1,2,0)
 ;;=2^J3260
 ;;^UTILITY(U,$J,358.3,8673,1,3,0)
 ;;=3^TOBRAMYCIN SULFATE PER 80 MG
 ;;^UTILITY(U,$J,358.3,8674,0)
 ;;=J7682^^68^586^42^^^^1
 ;;^UTILITY(U,$J,358.3,8674,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8674,1,2,0)
 ;;=2^J7682
 ;;^UTILITY(U,$J,358.3,8674,1,3,0)
 ;;=3^TOBRAMYCIN NON-COM UNIT 300 MG
 ;;^UTILITY(U,$J,358.3,8675,0)
 ;;=P9047^^68^586^2^^^^1
 ;;^UTILITY(U,$J,358.3,8675,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8675,1,2,0)
 ;;=2^P9047
 ;;^UTILITY(U,$J,358.3,8675,1,3,0)
 ;;=3^ALBUMIN (HUMAN), 25%, 50ML
 ;;^UTILITY(U,$J,358.3,8676,0)
 ;;=J3370^^68^586^45^^^^1
 ;;^UTILITY(U,$J,358.3,8676,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8676,1,2,0)
 ;;=2^J3370
 ;;^UTILITY(U,$J,358.3,8676,1,3,0)
 ;;=3^VANCOMYCIN HCL 500 MG
 ;;^UTILITY(U,$J,358.3,8677,0)
 ;;=J0636^^68^586^5^^^^1
 ;;^UTILITY(U,$J,358.3,8677,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8677,1,2,0)
 ;;=2^J0636
 ;;^UTILITY(U,$J,358.3,8677,1,3,0)
 ;;=3^CALCITRIOL INJ PER 0.1 MCG
 ;;^UTILITY(U,$J,358.3,8678,0)
 ;;=J0882^^68^586^11^^^^1
 ;;^UTILITY(U,$J,358.3,8678,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8678,1,2,0)
 ;;=2^J0882
 ;;^UTILITY(U,$J,358.3,8678,1,3,0)
 ;;=3^DARBEPOETIN ALFA,ESRD USE 1MCG
 ;;^UTILITY(U,$J,358.3,8679,0)
 ;;=J3490^^68^586^29^^^^1
 ;;^UTILITY(U,$J,358.3,8679,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8679,1,2,0)
 ;;=2^J3490
 ;;^UTILITY(U,$J,358.3,8679,1,3,0)
 ;;=3^LITHIUM CARBONATE
 ;;^UTILITY(U,$J,358.3,8680,0)
 ;;=J3490^^68^586^32^^^^1
 ;;^UTILITY(U,$J,358.3,8680,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8680,1,2,0)
 ;;=2^J3490
 ;;^UTILITY(U,$J,358.3,8680,1,3,0)
 ;;=3^MIDODRINE
 ;;^UTILITY(U,$J,358.3,8681,0)
 ;;=J0881^^68^586^12^^^^1
 ;;^UTILITY(U,$J,358.3,8681,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8681,1,2,0)
 ;;=2^J0881
 ;;^UTILITY(U,$J,358.3,8681,1,3,0)
 ;;=3^DARBEPOETIN ALFA,NON-ESRD USE 1 MCG
 ;;^UTILITY(U,$J,358.3,8682,0)
 ;;=J0885^^68^586^18^^^^1
 ;;^UTILITY(U,$J,358.3,8682,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,8682,1,2,0)
 ;;=2^J0885
 ;;^UTILITY(U,$J,358.3,8682,1,3,0)
 ;;=3^EPOETIN ALFA 1000 UNITS NON-ESRD
 ;;^UTILITY(U,$J,358.3,8683,0)
 ;;=J7060^^68^586^1^^^^1
